Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
Recruiting
Observational Study
LVAD
Frailty
GI Bleed
Right Heart Failure
Infections
Hypertension
Arrhythmias
Stroke
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 100
- Sex
- Any
- Study type
- Observational
- Participants needed
- 150 (estimated)
- Sponsor
- International Consortium of Circulatory Assist Clinicians · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing s…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 18 years of age or older
* Scheduled Heartmate 3 ® dLVAD implantation
Exclusion Criteria:
* \<18 years of age
* Scheduled for dLVAD that is NOT a Heartmate 3 (R) device
Contacts